BHCM
CSTL icon

Brevan Howard Capital Management’s Castle Biosciences CSTL Stock Holding History

Brevan Howard Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456K Buy
+18,560
New +$608K ﹤0.01% 1355
2025
Q4 		– Sell
-19,128
Closed -$436K – 1892
2025
Q3 		$436K Sell
19,128
-22,173
-54% -$450K ﹤0.01% 1357
2025
Q2 		$843K Buy
41,301
+29,096
+238% +$539K ﹤0.01% 1142
2025
Q1 		$244K Buy
+12,205
New +$302K ﹤0.01% 924
2024
Q4 		– Sell
-10,622
Closed -$303K – 1109
2024
Q3 		$303K Buy
+10,622
New +$270K ﹤0.01% 855

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's CSTL Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Castle Biosciences (CSTL) in Q1 2026: 18,560 shares worth $456K. The stake represents ﹤0.01% of the portfolio and ranks #1355 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in CSTL as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in CSTL in Q3 2024 and has held it in 5 quarters since. The position peaked at $843K in Q2 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Brevan Howard Capital Management held 18,560 shares of Castle Biosciences worth $456K as of Q1 2026.
  • Castle Biosciences was a new Brevan Howard Capital Management position in Q1 2026.
  • Castle Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1355 holding.
  • Brevan Howard Capital Management first reported a position in Castle Biosciences in Q3 2024 and has held it in 5 quarters since.
  • Brevan Howard Capital Management's Castle Biosciences position peaked at $843K in Q2 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.